Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
154.31B
Market cap154.31B
Price-Earnings ratio
19.90
Price-Earnings ratio19.90
Dividend yield
6.36%
Dividend yield6.36%
Average volume
40.67M
Average volume40.67M
High today
$27.42
High today$27.42
Low today
$27.00
Low today$27.00
Open price
$27.13
Open price$27.13
Volume
34.69M
Volume34.69M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 154.31B, Pfizer(PFE) trades at $27.06. The stock has a price-to-earnings ratio of 19.90 and currently yields dividends of 6.4%.

During the trading session on 2026-02-24, Pfizer(PFE) shares reached a daily high of $27.42 and a low of $27.00. At a current price of $27.06, the stock is +0.2% higher than the low and still -1.3% under the high.

Trading volume for Pfizer(PFE) stock has reached 34.69M, versus its average volume of 40.67M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.

PFE News

TipRanks 4h
RBC starts Pfizer at Underperform on ‘insurmountable’ patent cliff

As previously reported, RBC Capital initiated coverage of Pfizer (PFE) with an Underperform rating and $25 price target reflecting an “insurmountable” $15B-$20B...

The Motley Fool 10h
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive. Pfizer (PFE +1.18%) is one of the world's largest and most...

This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
Simply Wall St 24h
How Breakwater Trial Data At Pfizer Has Changed Its Oncology Investment Story

Pfizer recently reported positive progression-free survival data from Cohort 3 of its Phase 3 BREAKWATER trial, where BRAFTOVI plus cetuximab and FOLFIRI outper...

How Breakwater Trial Data At Pfizer Has Changed Its Oncology Investment Story

Analyst ratings

59%

of 29 ratings
Buy
31%
Hold
58.6%
Sell
10.3%

More PFE News

Simply Wall St 2d
Assessing Pfizer Valuation As Investors Revisit Mixed Returns And Oncology Growth Prospects

Advertisement Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus as investors reassess the stock after a period of mixed returns, wit...

Assessing Pfizer Valuation As Investors Revisit Mixed Returns And Oncology Growth Prospects
The Motley Fool 2d
My 5 Favorite Dividend Stocks to Buy Right Now

There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head. Does your portfolio need so...

My 5 Favorite Dividend Stocks to Buy Right Now
Nasdaq 3d
Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think

Pfizer (NYSE: PFE) offers a rare mix of scale, stability, and a 6% dividend yield that few large caps can match. With steady cash flow, modest valuation, and an...

Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think
Nasdaq 4d
Is Pfizer Stock an Underrated Healthcare Investment Play?

Key Points The stock offers a lofty 6.2% yield, and management has declared its intent to support its dividend. The pharmaceutical giant has fallen behind com...

Is Pfizer Stock an Underrated Healthcare Investment Play?
Nasdaq 5d
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?

Key Points Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through...

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?
TipRanks 5d
Pfizer initiated with an Underweight at Barclays

Barclays analyst Emily Field initiated coverage of Pfizer (PFE) with an Underweight rating and $25 price target Pfizer is “managing through a difficult period,”...

Simply Wall St 5d
Pfizer's BRAFTOVI Trial Win Adds Weight To Undervalued Oncology Story

Pfizer (NYSE:PFE) reported positive pivotal Phase 3 trial results for BRAFTOVI in combination with cetuximab and FOLFIRI in BRAF V600E-mutant metastatic colorec...

Pfizer's BRAFTOVI Trial Win Adds Weight To Undervalued Oncology Story

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.